Pfizer sues HHS over Medicare rules

Katie Adams –
Monday, June 29th, 2020
Print|Email.

Drugmakers are not enabled to subsidize copayments for Medicare patients, but they can contribute to nonprofits that provide copay aid.

Pfizer submitted a suit June 26 implicating HHS of blocking it from supplying financial aid to Medicare recipients for its two cardiovascular disease drugs.

According to the court file, HHS sees Pfizers efforts to assist Medicare recipients manage its Vyndaqel and Vyndamax drugs to be an unlawful kickback plan. Pfizer alleged HHS regulative action broke its constitutional rights to totally free speech and due procedure.

More articles on pharmacy: Cheap steroid in scarcity after being presumed as possible COVID-19 treatmentNovartis pays DOJ, SEC $347M in kickback scheme settlementEnsuring clinical trials include racially diverse individuals: 4 techniques.

Vyndaqel and Vyndamax treat transthyretin amyloid cardiomyopathy, a condition that can lead to progressive heart failure or death if left without treatment. They are amongst the most expensive heart problem drugs in the market.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by click on this link.